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Protocol
AbstrAct
Introduction Symptomatic knee osteoarthritis (OA) 
is common. Advanced knee OA is successfully treated 
with joint replacement surgery, but effectively managing 
mild to moderate knee OA can be difficult. Angiogenesis 
increases with OA and might contribute to pain and 
structural damage. Modifying angiogenesis is a potential 
treatment pathway for OA. The aim of the current study is 
to determine whether transcatheter arterial embolisation 
of abnormal neovasculature arising from the genicular 
arterial branches improves knee pain, physical function 
and quality of life in people with mild to moderate 
symptomatic knee OA.
Methods and analysis The study is a single centre, 
parallel-arm, double-blinded (participant and assessor), 
randomised controlled superiority trial with 1:1 random 
block allocation. Eligible participants have mild to 
moderate symptomatic knee OA and will be randomly 
assigned to receive either embolisation of aberrant 
knee neovasculature of genicular arterial branches or a 
placebo intervention. Outcome measures will be collected 
prior to the intervention and again 1, 6 and 12 months 
postintervention. The primary outcome is change in knee 
pain between baseline and 12 month assessment as 
measured by the Knee Injury and Osteoarthritis Outcome 
Score (KOOS). Secondary outcomes include change in 
self-reported physical function (KOOS), self-reported 
quality of life (KOOS, EuroQol: EQ-5D-5L), self-reported 
knee joint stiffness (KOOS), self-reported global change, 
6 min walk test performance, and 30 s chair-stand test 
performance. Intention-to-treat analysis will be performed 
including all participants as randomised. To detect a mean 
between group difference in change pain of 20% at the 
one year reassessment with a two-sided significance level 
of α=0.05 and power of 80% using a two-sample t-test, 
we require 29 participants per arm which allows for 20% 
of participants to drop out.
Ethics and dissemination Barwon Health Human 
Research Ethics Committee, 30 May 2016, (ref:15/101). 
Study results will be disseminated via peer-reviewed 
publications and conference presentations.
Trial registration number Universal trial number U1111-
1183-8503, Australian New Zealand Clinical Trials Registry, 
ACTRN12616001184460, approved 29 August 2016.
InTroducTIon
Knee osteoarthritis (OA) is common and its 
prevalence is rising due to an ageing popu-
lation and the obesity epidemic.1 In 2010, 
radiographically confirmed symptomatic 
knee OA affected approximately 3.8% of 
people worldwide, and knee and hip OA 
ranked as the 11th highest contributor to 
global disability.2 The prevalence and burden 
of knee OA presents a major challenge for 
health systems globally.2
Knee OA is a complex, multifactorial 
disease with no known cure. Knee OA risk 
factors include joint injury, bone and joint 
shape, muscle strength and mass, obesity, 
gender, metabolic factors, nutrition and 
vitamin factors, bone density, psychological 
health and occupation.3–5 Treatment seeks 
to manage symptoms, but adequate symptom 
control can be difficult to achieve.6 Core 
Strengths and limitations of this study
 ► First randomised controlled trial to investigate
vascular embolisation for treating knee pain
 ► Internal validity optimised by study design
 ► External validity limited by single-site study
 ► The study has implications for large numbers of
people with knee osteoarthritis
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evidence-based treatment options for knee OA include 
intra-articular corticosteroids, exercise (land based and 
water based), education, weight management, and oral 
medications such as paracetamol and non-steroidal 
anti-inflammatories.7 Joint replacement is generally 
reserved for those with severe joint disease, pain and 
functional limitations.8 9
An in-depth understanding of OA pathophysiology is still 
emerging.1 3 Recently, angiogenesis has been implicated 
in OA by contributing to structural damage, inflammation 
and pain.10 Angiogenesis is blood vessel outgrowth from 
pre-existing vasculature and is essential for growth, devel-
opment and tissue repair.10 However, in OA, angiogenesis 
increases in articular cartilage, synovium, meniscus, and 
osteophytes, and at the osteochondral junction.11–15 
Because angiogenesis is accompanied by sensory nerve 
growth, perivascular nerve growth into normally aneural 
structures such as articular cartilage and meniscus is 
thought to contribute to OA pain through chemical and 
mechanical stimulation of newly formed nerves. Modifying 
angiogenesis and associated nerve growth is a potential 
treatment pathway to affect the pathogenesis and symp-
toms of OA.10 Angiogenesis inhibitor treatment decreased 
pain-related behaviour in animal models.11 The mecha-
nism of symptomatic relief is unclear but could include 
reduced synovitis, reduced periarticular innervation and 
nociception, and maintaining the integrity of the osteo-
chondral junction.10 11 Okuno et al investigated the effects 
of embolising abnormal blood vessels about the knee on 
pain in people with mild to moderate knee OA.6 Fourteen 
participants received transcatheter arterial embolisa-
tion of abnormal branches of the genicular artery using 
imipenem and cilastatin sodium or 75 µm Embozene 
microsphere. WOMAC (Western Ontario and McMaster 
Universities Osteoarthritis Index) pain and function scores 
improved substantially at 1, 4 and 12 months post proce-
dure. No major adverse events occurred. One participant 
had a moderate subcutaneous haemorrhage at the punc-
ture site that resolved within 1 week.
The current study seeks to elaborate on Okuno et al’s 
single-arm trial6 by using a randomised controlled design 
with a larger cohort of people.
objecTIves
The primary objective of the study is to determine 
whether transcatheter arterial embolisation of abnormal 
neovasculature arising from the genicular arterial 
branches improves knee pain 12 months post interven-
tion compared with a placebo intervention.
A secondary objective is to determine whether transcath-
eter arterial embolisation of abnormal neovasculature 
arising from the genicular arterial branches compared 
with a placebo intervention improves knee pain 1 and 
6 months post intervention. Other secondary objectives 
are to determine whether the intervention compared 
with the placebo at 1, 6 and 12 months post intervention 
improves:
1. self-reported physical function;
2. self-reported quality of life;
3. self-reported knee joint stiffness;
4. self-reported global change;
5. six-minute walk test performance;
6. thirty-second chair stand test performance.
The tertiary objective of the study is to determine
whether transcatheter arterial embolisation of abnormal 
neovasculature arising from the genicular arterial 
branches compared with a placebo intervention reduces 
pharmacotherapy (frequency and dosage) for knee pain 
1, 6 and 12 months post intervention.
MeThods and analysIs
study design
The study is a single-centre, parallel-arm, double-blinded 
(participant and assessor), randomised controlled supe-
riority trial with 1:1 random block allocation. The study 
will be conducted at a large regional public health service 
in Victoria, Australia. Vascular embolisation is routinely 
conducted at the study site. Table 1 summarises the study 
schedule.
eligibility criteria
Eligible participants must have the following character-
istics:
1. 18–75 years of age;
2. grade 2 knee OA on X-ray (including Rosenberg
radiograph) as per Kellgren-Lawrence Grading
Scale16;
3. knee pain for at least 6 months;
4. moderate to severe unilateral knee pain:
a. ≥3/10 knee pain on at least half the days in the
preceding month according to an 11-point nu-
meric scale with 0 representing ‘no pain’ and 10
‘the worst pain imaginable’;
5. pain resistant to conservative treatment for at least
6 months:
a. Conservative treatment might include medi-
cation (eg, paracetamol, anti-inflammatories),
intra-articular injections, physiotherapy or exer-
cise, or weight loss;
6. willing, able and mentally competent to provide
informed consent (able to read and understand
the Patient Information and Consent Form which
is written in English language).
People who have the following characteristics are not 
eligible:
1. local infection;
2. active malignancy;
3. rheumatoid arthritis or seronegative arthropathies;
4. prior ipsilateral knee surgery excluding arthroscopic 
surgery more than 6 months ago;
5. ipsilateral knee intra-articular injection in the last
6 months;
6. grade 3 or 4 knee OA on X-ray as per Kellgren-
Lawrence Grading Scale;16
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7. pregnant or trying to become pregnant during the
study period;
8. known history of allergy to contrast media;
9. reduced kidney function or failure (chronic or
acute):
a. estimated glomerular filtration rate <30 ml/
min/1.73 m2;
10. body weight greater than 200 kg;
11. platelets <100×109/L;
12. international normalised ratio >1.5;
13. approved for knee joint replacement surgery;
14. moderate to severe pain in other lower limb joints;
15. history of allergy to carbapenem (eg, imipenem,
ertapenem or meropenem), or having an immediate 
or severe hypersensitivity reaction to a penicillin or
cephalosporin antibiotic;
16. history of seizures or using valproate.
Participants will be recruited at the study site’s physio-
therapist-led outpatient screening clinic that routinely 
assesses people’s eligibility for knee joint replacement 
surgery following referral from the person’s general 
practitioner or rheumatologist. Physiotherapists will be 
trained by study investigators to assess and record partic-
ipant eligibility and provide eligible participants with 
written information regarding the study. Physiotherapists 
will receive training from the principal investigator to 
grade knee X-rays with the Kellgren-Lawrence scale in 
a manner similar to that used by others.17 Physiothera-
pists will receive descriptions of the scale, together with 
X-ray examples of each grade. An orthopaedic doctor
will be provided with the same training material as the
physiotherapist and will also grade X-rays of poten-
tial participants. The physiotherapist and orthopaedic 
doctor will discuss any discrepancies until consensus is 
reached. The principal investigator will adjudicate if the 
physiotherapist and orthopaedic doctor cannot reach 
consensus regarding the grading. A study coordinator or 
investigator will guide interested people through written 
informed consent. Recruitment is expected to occur over 
an 18-month period, commencing in 2017.
Participation in the study is voluntary; no financial 
incentives will be offered. The participant’s general 
practitioner will be informed by letter that the patient is 
taking part in the study; the general practitioner will not 
be informed of group allocation.
randomisation
People who meet eligibility requirements and provide 
informed consent will be randomly allocated to either 
intervention or control groups with a 1:1 allocation ratio. 
The allocation sequence will be computer generated by 
the trial statistician (SEL) prior to trial commencement 
and use randomly selected block sizes. Block sizes will 
not be disclosed to the interventionalist, assessors or 
other investigators. Allocation will be concealed until 
immediately prior to the participant’s intervention, at 
which time the interventionalist will access the alloca-
tion code for that participant via the web-based project 
and data management tool.18 Participants randomised to 
the control group will be offered the intervention at the 
completion of the study should it demonstrate effective-
ness.
Table 1 Study schedule
Prerandomisation Day 0
Postintervention
1 month 6 months 12 months
Enrolment
 Eligibility screen X
 Informed consent X
 Randomisation X
Interventions
 Embolisation X
 Placebo X
Assessments
 Demographic variables X
 KOOS X X X X
 EQ-5D-5L X X X X
 Global change X X X X
 Six-minute walk test X X X X
 Thirty-second chair stand test X X X X
 Analgesia X X X X
EQ-5D-5L: EuroQol.
Global change: overall change, change in pain, change in physical function.
KOOS, Knee Injury and Osteoarthritis Outcome Score (five scales: pain, symptoms, function in daily living, function in sports and recreational 
activities, quality of life).
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blinding
Participants and assessors will be blinded to group allo-
cation throughout the study. Due to the nature of the 
intervention, it is not possible to blind the interven-
tionist to group allocation. To assess the effectiveness of 
blinding, participants will be asked within 4 hours of the 
intervention which group they believed they were allo-
cated to, and again 1 and 12 months post intervention.
Interventions
The treatment group will receive angiography and 
embolisation; the control group will receive a placebo 
embolisation procedure. One interventional radiologist 
(SL), who is trained in vascular embolisation, will perform 
all procedures. The procedure, real or placebo, will take 
30–60 min to complete.
Participants in the treatment group will receive light 
sedation with midazolam and fentanyl and a local anaes-
thetic injected into their groin. Femoral artery access 
will be obtained with a 3 French sheath and a microca-
theter introduced. An angiogram will identify abnormal 
knee neovasculature arising from the genicular arterial 
branches. The abnormal vessels will be embolised with 
a suspension of 0.5 g imipenem and cilastatin sodium 
(Primaxin; Merck & Co, Whitehouse Station, New Jersey, 
USA) in 5 mL of iodinated contrast agent (prepared by 
pumping syringes for 10 s) by injecting 0.2 mL incre-
ments until blood flow stagnates. The guide wire will be 
removed. A dressing will be applied to the puncture site.
Participants in the control group will receive light seda-
tion with midazolam and fentanyl and a local anaesthetic 
injection and incision into their groin. The radiologist 
will then pretend to insert a guide wire and catheter 
into the femoral artery and complete the embolisation 
procedure. No wire or catheter will be introduced. No 
radiation will be used. No contrast will be administered. 
During the placebo procedure, the participant will view 
prerecorded video images of an angiogram and genicular 
artery vascular embolisation. The duration of the placebo 
procedure will match the treatment group. A dressing will 
be applied to the incision site.
All participants will be monitored for 4 hours post proce-
dure and any adverse events documented and managed. 
It is anticipated that most participants will be discharged 
home 4 hours post procedure.
outcome measures and assessment time points
Outcome measures will be collected 1–2 weeks before the 
intervention and 1, 6 and 12 months after the interven-
tion.
The primary outcome is change in knee pain between 
baseline and 12-month follow-up assessments. Pain will be 
assessed with the Knee injury and Osteoarthritis Outcome 
Score (KOOS). The KOOS is a condition-specific, self-ad-
ministered questionnaire that is commonly used in knee 
OA clinical trials.19
Change in KOOS pain scores at 1 and 6 months 
post intervention is a secondary outcome. Other secondary 
outcomes include change at 1, 6 and 12 months of assess-
ment for:
1. self-reported physical function: KOOS Function in
Daily Living scale and KOOS Function in Sport and
Recreation scale19;
2. self-reported quality of life: KOOS Quality of Life
scale19 and EQ-5D-5L20;
3. self-reported knee joint stiffness: KOOS Symptoms
scale19;
4. self-reported global changes: overall change,
change in knee pain, change in physical function
using a 7-point ordinal scale designed by the
investigators and based on a scale used by others21;
5. six-minute walk test performance22;
6. improved 30 s chair stand test performance23.
The tertiary outcome of change in pharmacotherapy to
treat knee pain will be determined 1, 6 and 12 months 
post intervention by the participant’s report of the 
frequency and dosage of medication taken. The study 
will not attempt to modify pharmacotherapy which will 
be determined by the participant and their relevant 
primary health professional. Participants in the interven-
tion group will receive an MRI of their affected knee 12 
months post intervention.
A research assistant, trained by the study investigators, 
will collect study data in person with each participant 
according to the pilot-tested study protocol. Participants 
will complete standardised questionnaires in paper format 
with assistance offered by the research assistant as 
required. Performance-based measures will be collected 
by the research assistant using standardised protocols. 
The research assistant will enter data into REDCap, the 
study’s password-protected electronic data collection and 
management tool hosted at Barwon Health.18
The study will collect baseline demographic informa-
tion including age, sex, height, body weight, medical 
comorbidities and highest educational status.
The study will record, but not attempt to modify 
throughout the study period, participants’ involvement 
in other treatment options for knee pain such as physio-
therapy.
Once participants have enrolled in the study and 
undergone the intervention, every reasonable effort will 
be made to reassess them for the entire study period. 
Research assistants will attempt to contact participants 
a maximum of four times over a 3-month period using 
phone, email or mail before they are considered lost to 
follow-up. Participants may withdraw from the study at 
any time and for any reason. Participants will be invited, 
though not required to indicate reasons for withdrawal. 
Participants wishing to withdraw from the study will be 
invited to complete questionnaire assessments via mail 
rather than attending reassessment/s in person.
adverse events and data safety and monitoring
An adverse event refers to an untoward occurrence during 
the study, which may or may not be causally related to 
the intervention.24 We will collect information relating 
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to adverse events from the baseline assessment until the 
participant completes the 12-month postintervention 
assessment. Information regarding all adverse events will 
be collected at the time of the intervention and at each 
follow-up assessment. Participants will be asked in writing 
to inform the study coordinator of adverse events that 
occur in the interim between planned assessments and 
each participant’s general practitioner/family doctor will 
be informed of the study in writing and asked to notify the 
study coordinator if adverse events occur. Serious adverse 
events (SAE) are those which result in death, are imme-
diately life threatening, require hospitalisation, result in 
persistent or significant disability or incapacity, or have 
important clinical sequelae. SAE will be reported to the 
Data and Safety Management Board (DSMB) and the 
organisation’s Human Research Ethics Committee within 
24 hours of the event becoming known to the investiga-
tors. All adverse events will be reported to the DSMB once 
all participants have completed the 12-month assessment. 
Study procedures will be audited by one investigator at 
least annually and any deviations compromising the 
fidelity of the study will be reported to the investigation 
team and where appropriate the DSMB. Annual reports 
of the study’s progress will be sent to the organisation’s 
Human Research Ethics Committee.
A DSMB has been established. DSMB membership is 
exclusive of the study investigators and includes two senior 
radiologists, one of whom is an interventional radiologist, 
a senior radiographer and a senior orthopaedic surgeon. 
DSMB members have no competing interests with the 
study. The DSMB’s main function is to oversee trial safety. 
The study investigators will inform the unblinded DSMB 
of any SAE and the DSMB will recommend to the investi-
gators whether to modify or cease the study.
statistical analysis plan
Intention-to-treat analysis will be performed and include 
all participants as randomised. The primary analysis will 
assess differences between the two treatment arms for 
percentage change in KOOS pain scores from baseline 
to 12-month assessment using a two-sample t-test if no 
dropouts occur and all data are available on each partic-
ipant. Normality of the outcomes will be assessed and if 
the assumptions are not met, the primary analysis will be 
conducted using the Wilcoxon rank-sum test. In the case 
of dropouts or missing data at 12 months, the primary 
analysis will be conducted using linear regression, with 
random effects accounting for intraindividual correla-
tions.
Secondary outcomes assessed at baseline and follow-up 
will first be analysed as the difference between the two 
treatment arms in percentage change from baseline 
to 12-month assessment using two-sample t-tests if no 
dropouts occur and all data are available on each partic-
ipant. Normality of the outcomes will be assessed and if 
the assumptions are not met, analyses will be conducted 
using the Wilcoxon rank-sum test. In the case of drop-
outs or missing data, analyses will be conducted under a 
linear regression model, with random effects accounting 
for intraindividual correlations. Outcome data that are 
available at multiple time points will also be analysed 
using linear regression models, with random effects 
accounting for intraindividual correlations. Differences 
between intervention and placebo arms will be analysed 
and presented for each time point using a time-by-inter-
vention product term.
Participant reported global change since the interven-
tion will be dichotomised as ‘improved’ (moderately or 
much better) or ‘not improved’ (slightly better or below). 
Between-group comparisons will be made using log bino-
mial regression and presented as relative risks.21
Tests will be two sided and considered significant if p 
values are less than 0.05.
sample size
The sample size was calculated on the basis of the 
primary outcome. Using data provided by Okuno et al,6 
we estimated that the SD of change in pain 12 months 
post intervention was 19.9%. Given the small sample 
size and the observational nature of Okuno et al’s study, 
we chose a conservative approach and used the upper 
limit of the 80% CI for the SD. The SD was calculated 
via bootstrapping and was equal to 23.9%. For the mean 
between-group difference for change in pain, we used a 
minimum important difference (MID) of 20%. KOOS 
guidelines suggest a MID of 8–10 points for sample 
size calculations,25 and assuming baseline pain scores 
between 48 and 70 for adults with knee OA,26 27 MID as 
a percentage of baseline pain would be 11%–21%, from 
which we chose a conservative estimate of 20%. To detect 
a mean between-group difference of 20% for change 
in pain (SD=23.9%) with a two-sided significance level 
of α=0.05 and power of 80% using a two-sample t-test, 
we require 24 participants per arm. Allowing for a 20% 
dropout rate, 29 participants per treatment arm will be 
recruited, equalling 58 participants in total.
ethics and dissemination
Barwon Health Human Research Ethics Committee, 
Geelong, Australia, approved the study including the 
protocol and the participant information and consent 
form (reference 15/101, 30 May 2016). The ethics 
committee will be notified of any adverse events relating 
to the study or any changes to the study protocol. The 
study complies with the National Statement on Ethical 
Conduct in Research.28 The study is registered with the 
Australian New Zealand Clinical Trials Registry.29
All investigators and the trial statistician will have access 
to the final dataset. Key study results will be shared with 
interested participants in writing using plain English. 
Results will be disseminated at national and international 
conferences and in peer-reviewed journals. Authorship 
eligibility for disseminated material will be determined 
according to international criteria.30
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